Fan Site: Inspired, Not Endorsed, By Rakesh Jhunjhunwala

Best Pharma Stocks With Buy/ Hold Recommendation



Daljeet Kohli and his team at IndiaNivesh have conducted a comprehensive preview of the Q2FY15E Results of the best pharma stocks and given buy/ hold recommendations




The report explains in detail the expectations of each stock and what its prospects will be in the near future. Thereafter, the report also gives the target price of each stock and provides for a buy or hold recommendation.

All the top-quality stocks, namely, Ajanta Pharma, Alembic Pharma, Aurobindo Pharma, Biocon, Cadila, Cipla, Divis Lab, Dr Reddy, Glenmark, Ipca Lab, JB Chemicals, Jubilant LifeSciences, Lupin, Sharon Bio‐medicine, Shilpa Medicare, Sun Pharma and Torrent are covered in the report.

Click here to download Q2FY15E Results Preview Of Pharma Sector By IndiaNivesh
investments, Large Cap, Mid Cap, Multibagger, Portfolio, Top Picks    , , , , , , ,

No Comments Yet

Leave a Reply

Your email address will not be published. Required fields are marked *

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 495 other subscribers

RSS Stocks Talk Forum

  • Sunil Singhania & Madhu Kela are bullish about Himatsingka Seide
    Sunil Singhania & Madhu Kela are bullish about Himatsingka Seide. Singhania's Abakkus Fund holds 6.78% worth ₹137 Cr. Kela's Cohesion MK Fund holds 4.07% worth ₹82 Cr. M-Cap is ₹2100 Cr. Promoters hold 37%. Co is dominant in branded Home Textile with a 'fibre to shelf' model
  • Suraj Estate Developers has a robust project lineup & launch pipeline. TP ₹992 (+73%)
    Suraj Estate Developers has a robust project lineup & launch pipeline, leadership position in redevelopment projects, strong cost advantage, proven track record, huge addressable market and healthy Balance Sheet with predictable cash flows. TP ₹992 (+73%) Download research report... Suraj Estate Developers has a robust project lineup & launch pipeline. TP ₹992 (+73%)
  • DCX Systems has the ability to become a key player in EMS space. TP ₹466 (+54%)
    DCX Systems has the ability to become a key player in EMS space with huge potential in railway & defence. It has ability to deliver high value complicated & critical products for leading defense players L&T & Lockheed. Order book ₹3000 Cr. TP ₹466 (+54%) Download... DCX Systems has the ability to become a key […]
Disclaimer: This is a Fan Site in Rakesh Jhunjhunwala's name. Rakesh Jhunjhunwala is not associated with us and is in no way aware, accountable or responsible for what is stated here. Further, nothing here constiutes investment advice for you to act on. Also, we have a vested interest, and are extremely biased, in everything that we say. So Mind It!